JPH044293B2 - - Google Patents

Info

Publication number
JPH044293B2
JPH044293B2 JP56061541A JP6154181A JPH044293B2 JP H044293 B2 JPH044293 B2 JP H044293B2 JP 56061541 A JP56061541 A JP 56061541A JP 6154181 A JP6154181 A JP 6154181A JP H044293 B2 JPH044293 B2 JP H044293B2
Authority
JP
Japan
Prior art keywords
drug
wall
compartment
formulation
passageway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56061541A
Other languages
English (en)
Japanese (ja)
Other versions
JPS56167617A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPS56167617A publication Critical patent/JPS56167617A/ja
Publication of JPH044293B2 publication Critical patent/JPH044293B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP6154181A 1980-04-25 1981-04-24 Permeation device Granted JPS56167617A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/143,644 US4265874A (en) 1980-04-25 1980-04-25 Method of delivering drug with aid of effervescent activity generated in environment of use

Publications (2)

Publication Number Publication Date
JPS56167617A JPS56167617A (en) 1981-12-23
JPH044293B2 true JPH044293B2 (forum.php) 1992-01-27

Family

ID=22504961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6154181A Granted JPS56167617A (en) 1980-04-25 1981-04-24 Permeation device

Country Status (11)

Country Link
US (1) US4265874A (forum.php)
EP (1) EP0040899B1 (forum.php)
JP (1) JPS56167617A (forum.php)
AT (1) ATE9267T1 (forum.php)
DE (1) DE3165901D1 (forum.php)
DK (1) DK152482C (forum.php)
ES (2) ES267593Y (forum.php)
GR (1) GR73519B (forum.php)
IE (1) IE51216B1 (forum.php)
NZ (1) NZ196561A (forum.php)
PT (1) PT72796B (forum.php)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150137871A (ko) * 2014-05-30 2015-12-09 디씨에스이엔지 주식회사 회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치

Families Citing this family (731)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
US4478596A (en) * 1982-11-26 1984-10-23 Michelson Paul E Delivery system for physiologically active agents
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
JPH075457B2 (ja) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
US4670578A (en) * 1983-08-29 1987-06-02 Merck & Co., Inc. Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters
EP0137364A3 (en) * 1983-09-23 1986-10-22 Merck & Co. Inc. Suppository form of an osmotic therapeutic system
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
GB2150434B (en) * 1983-12-01 1987-11-04 Alza Corp Constant rate release systems
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4595583A (en) * 1984-03-19 1986-06-17 Alza Corporation Delivery system controlled administration of beneficial agent to ruminants
EP0166354B1 (en) 1984-06-26 1992-08-05 Merck & Co. Inc. Benzofused lactam compounds and pharmaceutical compositions containing them
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4675174A (en) * 1985-08-16 1987-06-23 Alza Corporation Veterinary dispenser delivering beneficial agent by gas power generated in situ
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
US4847093A (en) * 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US5143908A (en) * 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US5099063A (en) * 1986-11-05 1992-03-24 Merck & Co., Inc. Certain phosphinic acid derivatives having antibacterial activity
US4715994A (en) * 1986-11-05 1987-12-29 Merck & Co., Inc. Novel antibacterial agents and potentiators of carbapenem antibiotics
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US5499979A (en) * 1987-06-25 1996-03-19 Alza Corporation Delivery system comprising kinetic forces
US5041644A (en) * 1987-07-06 1991-08-20 Merck & Co., Inc. Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
JPS6413097A (en) * 1987-07-06 1989-01-17 Mitsubishi Chem Ind Phosphonic acid derivative
DE3873278T2 (de) 1987-09-22 1993-02-25 Merck & Co Inc Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
US5030732A (en) * 1988-03-03 1991-07-09 Merck & Co., Inc. Aminoethylphosphinic acid derivatives
CH675537A5 (forum.php) * 1988-03-25 1990-10-15 Ciba Geigy Ag
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
US5145990A (en) * 1988-10-28 1992-09-08 Merck & Co., Inc. Phosphorous containing dhp enzyme inhibitors
US4962097A (en) * 1988-10-28 1990-10-09 Merck & Co., Inc. Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
US5147867A (en) * 1988-10-28 1992-09-15 Merck & Co., Inc. Phosphorus containing enzyme inhibitors
US4942039A (en) * 1989-05-09 1990-07-17 Miles Inc. Effervescent analgesic antacid composition having reduced sodium content
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5089530A (en) 1990-08-03 1992-02-18 Merck & Co., Inc. Novel fermentation product with antiparasitic activity
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5639782A (en) * 1992-03-04 1997-06-17 Center For Innovative Technology Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
JPH08502243A (ja) 1992-07-13 1996-03-12 サイトメッド，インコーポレイテッド 炎症性および免疫性疾患の治療のための２，５‐ジアリールテトラヒドロ‐チオフェン、‐フランおよび類似体
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
US5750565A (en) 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US6348571B1 (en) 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
KR19990014865A (ko) * 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
US5756540A (en) * 1995-06-02 1998-05-26 Mcw Research Foundation, Inc. Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US6372713B1 (en) 1995-09-08 2002-04-16 The Board Of Trustees Of Northwestern University Anti-depressant effects of corticotropin release inhibiting factor
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6723531B2 (en) * 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5902605A (en) * 1996-04-18 1999-05-11 Alza Corporation Drug delivery device with minimal residual drug retention
US5785688A (en) * 1996-05-07 1998-07-28 Ceramatec, Inc. Fluid delivery apparatus and method
US5939460A (en) * 1996-07-08 1999-08-17 Idun Pharmaceuticals, Inc. Method of inhibiting NADPH oxidase
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
AU746790B2 (en) 1996-09-10 2002-05-02 Medinox, Inc. Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
US5858402A (en) * 1997-02-11 1999-01-12 Medinox, Inc. Methods for in vivo reduction of cyanide levels and compositions useful therefor
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US7105496B2 (en) 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CA2305703A1 (en) 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
JP2001519386A (ja) 1997-10-15 2001-10-23 トーマス・ジェファーソン・ユニバーシティ 哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット
US6750201B1 (en) * 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6984773B1 (en) * 1998-01-09 2006-01-10 The Salk Institute For Biological Studies Transgenic mice expressing a human SXR receptor polypeptide
US6756491B2 (en) 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
US6287605B1 (en) * 1998-04-17 2001-09-11 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treatment and prevention of HIV-1 infection
AU3979099A (en) 1998-05-11 1999-11-29 Philadelphia Health & Education Corporation (mct-1), a human oncogene
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20030064917A1 (en) * 1998-07-23 2003-04-03 Crawford Susan E. Methods and compositions for inhibiting angiogenesis
AU5561999A (en) 1998-08-13 2000-03-06 Wistar Institute, The Methods for reducing atherosclerotic plaques
US6565854B2 (en) 1998-08-13 2003-05-20 Philadelphia Health And Education Corporation Antimicrobial histone H1 compositions, kits, and methods of use thereof
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US20020138856A1 (en) * 1998-10-23 2002-09-26 Northwestern University Compositions and methods useful for treatment of depressive disorder based on an animal model
ES2295005T3 (es) 1999-01-13 2008-04-16 Alchemia Oncology Pty Limited Uso de hialuronano para la preparacion de un medicamento para la mejora de la eficacia de farmacos citotoxicos.
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
AU2732000A (en) 1999-01-19 2000-08-01 Children's Hospital Of Philadelphia, The Reverse gene therapy
US7282489B2 (en) * 2000-01-19 2007-10-16 The Children's Hospital Of Philadelphia Compositions and methods for performing reverse gene therapy
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
CA2364653A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6221855B1 (en) 1999-03-11 2001-04-24 Wake Forest University Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
EP1180114B1 (en) 1999-04-27 2011-09-21 The Trustees of The University of Pennsylvania Use of resisitin specific antibodies in the treatment of diabetes
US6420545B1 (en) 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US7033780B1 (en) * 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7160694B2 (en) 1999-06-14 2007-01-09 Millennium Pharmaceuticals, Inc. Nucleic acids encoding TANGO405 and functional fragments and uses thereof
US6964854B1 (en) 1999-07-13 2005-11-15 Science & Technology Corporation Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
AU782401B2 (en) 1999-10-08 2005-07-28 Taiji Biomedical, Inc. Methods of enhancing chemotherapy
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
ES2339326T3 (es) 1999-10-12 2010-05-19 Chemocentryx, Inc. Receptor de quimioquina.
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
JP3417370B2 (ja) 1999-12-09 2003-06-16 株式会社村田製作所 非可逆回路素子及び通信機装置
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US20030212021A1 (en) * 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
JP2001320205A (ja) 2000-03-02 2001-11-16 Murata Mfg Co Ltd 非可逆回路素子および通信装置
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
PL358579A1 (en) * 2000-04-07 2004-08-09 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
AU778368B2 (en) * 2000-05-15 2004-12-02 Darwin Discovery Limited Hydroxamic acid derivatives
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
AU2001275043A1 (en) 2000-05-31 2001-12-11 Drugtech Corporation Mineral supplement
WO2001097752A2 (en) * 2000-06-20 2001-12-27 The Trustees Of The University Of Pennsylvania Compositions comprising urokinase for modulating muscle contractility and angiogenisis
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
CN1446227B (zh) 2000-07-19 2011-10-05 先端研究与技术学院 新型成纤维细胞生长因子(fgf23)及其使用方法
AU2001290629A1 (en) * 2000-09-07 2002-03-22 Boehringer Ingelheim International G.M.B.H Heat shock response and virus replication
WO2002026240A2 (en) * 2000-09-26 2002-04-04 Sidney Kimmel Cancer Center Inhibition of antigen presentation with poorly catabolized polymers
US20040102367A1 (en) * 2001-02-23 2004-05-27 Gage Fred H Gene expression system based on chimeric receptors
EP1387680A4 (en) * 2001-03-05 2010-01-13 Transtech Pharma Inc AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE
AU2002248557A1 (en) * 2001-03-05 2002-09-19 Transtech Pharma, Inc. High level insect expression of rage proteins
CN1494425B (zh) * 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
US7294472B2 (en) * 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6727287B2 (en) 2001-04-16 2004-04-27 Pts International, Inc. Toluene sulfonamide-containing anti-tumor composition and method of use thereof
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
CN1157388C (zh) * 2001-05-29 2004-07-14 北京大学 哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用
RU2259825C9 (ru) 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003007793A2 (en) * 2001-07-17 2003-01-30 Yale University Compositions, methods, and kits related to treating and diagnosing hypertension
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
GB0119396D0 (en) * 2001-08-09 2001-10-03 Celltech R&D Ltd Hydroxamic acid derivatives
CA2456977C (en) * 2001-08-16 2011-06-07 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
US9056048B2 (en) * 2001-08-16 2015-06-16 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy
CN1578677A (zh) * 2001-08-27 2005-02-09 美迪泰克研究有限公司 改良的治疗方案
US20030069071A1 (en) * 2001-09-28 2003-04-10 Tim Britt Entertainment monitoring system and method
ES2326040T3 (es) * 2001-10-19 2009-09-29 Isotechnika Inc. Sintesis de analogos de ciclosporina.
US6555563B1 (en) 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
DE60335869D1 (de) 2002-04-11 2011-03-10 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
US7378438B2 (en) * 2002-04-19 2008-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
EP1501511A4 (en) * 2002-05-06 2006-06-07 Univ Washington METHODS OF TREATING GLAUCOMA AND OTHER CONDITIONS INDUCED BY EXPRESSION OF NOS-2 BY INHIBITING THE EGFR PATHWAY
AUPS234402A0 (en) * 2002-05-15 2002-06-13 Auckland Uniservices Limited Anti-tumour polycyclic carboxamides
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US6727241B2 (en) 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
ES2329356T3 (es) 2002-06-12 2009-11-25 Chemocentryx, Inc. Derivados de piperazina 1-arilo-4-sustituidos utilizados como antagonistas de ccr1 para el tratamiento de enfermedades inflamatorias e inmunitarias.
US6620813B1 (en) 2002-06-21 2003-09-16 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
US20040077691A1 (en) * 2002-06-21 2004-04-22 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
NZ539211A (en) 2002-10-04 2008-05-30 Prana Biotechnology Ltd Neurologically-active compounds
AU2003284166A1 (en) * 2002-10-23 2004-05-13 University Of Hawaii Methods for diagnosing and treating pre-term labor
WO2004037843A2 (en) * 2002-10-25 2004-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
AU2003284984B2 (en) 2002-10-30 2008-10-23 Merck Sharp & Dohme Corp. Gamma-aminoamide modulators of chemokine receptor activity
US20040138301A1 (en) 2002-11-08 2004-07-15 Hansen Birgit Sehested Chemical uncouplers for the treatment of obesity
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
EP2256116A3 (en) * 2002-11-18 2011-11-16 ChemoCentryx, Inc. Aryl sulfonamides
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
BR0315688A (pt) * 2002-11-22 2005-09-06 Japan Tobacco Inc Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
AU2003286389A1 (en) * 2002-11-29 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
CA2503172A1 (en) 2002-12-20 2004-07-08 Arakis Ltd. Benzoxazocines and their use as monoamine-reuptake inhibitors
CN1747929B (zh) * 2002-12-20 2010-04-28 坎莫森特里克斯公司 趋化因子i-tac或sdf-1结合于ccxckr2受体的抑制剂
EP1594560A4 (en) * 2003-01-09 2007-06-06 Univ Pennsylvania COMPOSITIONS, METHODS AND KITS FOR INCREASING THE IMMUNOGENICITY OF A BACTERIA VACCINE VECTOR
AU2003900927A0 (en) * 2003-02-28 2003-03-13 Biodiem Ltd Growth promotion method
WO2004084812A2 (en) * 2003-03-21 2004-10-07 Joullie Madeleine M Tamandarin analogs and fragments thereof and methods of making and using
JP2006522746A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 置換されたアミドの薬学的使用
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
WO2005013907A2 (en) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
JP2007501813A (ja) 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ 新生血管形成と関連した症状を治療および診断するためのインターロイキン−２０
US8071535B2 (en) * 2003-09-12 2011-12-06 The Regents Of The University Of California Guanidinium derivatives for improved cellular transport
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
JP2007532471A (ja) 2003-09-30 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ 新規メラノコルチンレセプターアゴニスト
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
EP1699436A2 (en) * 2003-12-12 2006-09-13 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
TW200533668A (en) * 2003-12-15 2005-10-16 Theramex 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
EP1786833A4 (en) 2004-03-19 2009-02-25 Univ Yale DETECTION, INSULATION AND USE OF RENALASE (MONOAMINOXIDASE C)
JP2007530563A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド （ｓ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
WO2005092333A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
KR101258298B1 (ko) * 2004-06-01 2013-04-25 유니버시티 오브 버지니아 페이턴트 파운데이션 암 및 혈관형성의 이중 소분자 억제제
BRPI0512040A (pt) 2004-06-14 2008-02-06 Zoser B Salama composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
EP1776108A1 (en) * 2004-06-23 2007-04-25 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US8507411B2 (en) * 2004-06-24 2013-08-13 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
AU2005258280B2 (en) * 2004-06-24 2009-12-10 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
ATE435853T1 (de) * 2004-07-02 2009-07-15 Allergan Inc Prostaglandinanaloga
UA92154C2 (ru) * 2004-08-03 2010-10-11 Транстек Фарма, Инк. Rage-слитые белки и способы их применения
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO2006137839A2 (en) 2004-08-24 2006-12-28 Merck & Co., Inc. Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
BRPI0515332A (pt) 2004-09-17 2008-07-22 Univ Massachusetts composições e seus usos para deficiências das enzimas lisossÈmicas
WO2006039252A2 (en) * 2004-10-01 2006-04-13 Merck & Co., Inc. Compositions and methods for treating ophthalmic diseases
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
US7612082B2 (en) * 2004-10-28 2009-11-03 Allergan, Inc. Prostaglandin EP4 antagonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
AU2006204038A1 (en) * 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
MX2007008474A (es) 2005-01-14 2008-02-19 Chemocentryx Inc Sulfonamidas de heteroarilo y ccr2.
TWI386208B (zh) * 2005-04-18 2013-02-21 Allergan Inc 治療性的經取代環戊酮
EP1871804B1 (en) * 2005-04-21 2013-08-28 ChemoCentryx, Inc. Antibodies that bind ccx-ckr2
EP1871362A2 (en) 2005-04-27 2008-01-02 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
EP1877050B1 (en) * 2005-05-06 2011-07-06 Allergan, Inc. Substituted beta-lactams and their use in medicine
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
EP1883394B1 (en) 2005-05-23 2018-03-28 SDG, Inc. Lipid construct for delivery of insulin to a mammal
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ563454A (en) * 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070021357A1 (en) * 2005-06-17 2007-01-25 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
MX2007016270A (es) 2005-06-27 2008-03-05 Amgen Inc Compuestos aril nitrilo anti-inflamatorios.
WO2007005176A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
ATE518853T1 (de) 2005-08-12 2011-08-15 Schering Corp Verbindungen zur behandlung entzündlicher erkrankungen
WO2007025166A2 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
WO2008108842A1 (en) 2007-02-28 2008-09-12 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
JP5259408B2 (ja) 2005-08-29 2013-08-07 ユニバーシティ オブ バージニア パテント ファンデーション リソフィリン類縁体とその使用方法
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
US8623354B2 (en) 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US20090209624A1 (en) * 2005-10-24 2009-08-20 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
WO2007059108A2 (en) 2005-11-10 2007-05-24 Chemocentryx, Inc. Substituted quinolones and methods of use
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
JP2009520833A (ja) * 2005-12-20 2009-05-28 ギリード・コロラド・インコーポレーテッド ４，７−ジヒドロチエノ［２，３−ｂ］ピリジン化合物及び医薬組成物
US7323477B2 (en) * 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
ATE468121T1 (de) * 2006-02-21 2010-06-15 Astrum Therapeutics Pty Ltd Zusammensetzungen zur verringerung des blutglukosespiegels und zur behandlung von diabetes
US8962643B2 (en) * 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
AU2007226957B2 (en) 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
US20070225246A1 (en) * 2006-03-27 2007-09-27 Denu John M O-acetyl-ADP-ribose non-hydrolyzable analogs
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CA2618488C (en) * 2006-04-11 2010-07-13 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
NZ572591A (en) 2006-04-14 2012-01-12 Prana Biotechnology Ltd 3N-substituted 8-hydroxy-quinazolin-4-ones
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US20090016981A1 (en) 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
US7476755B2 (en) 2006-05-04 2009-01-13 Allergan, Inc. Therapeutic compounds
EP2024358B1 (en) 2006-05-09 2014-11-05 Merck Sharp & Dohme Corp. Substituted spirocyclic cgrp receptor antagonists
US7547727B2 (en) 2006-05-22 2009-06-16 Allergan, Inc. Therapeutic cyclopentane derivatives
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
US7553860B2 (en) * 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
DK2035390T3 (en) 2006-07-05 2016-01-04 Merial Inc 1-aryl-5-alkylpyrazolderivatforbindelser, methods of making and methods of use thereof
JP5532302B2 (ja) 2006-07-10 2014-06-25 アラーガン インコーポレイテッド 治療化合物
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
NZ574759A (en) 2006-07-14 2010-10-29 Chemocentryx Inc Triazolyl phenyl benzenesulfonamides
US7700627B2 (en) * 2006-07-26 2010-04-20 Allergan, Inc. Therapeutic substituted lactams
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US7985767B2 (en) * 2006-09-06 2011-07-26 Allergan, Inc. Therapeutic amides
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2076525A2 (en) * 2006-10-06 2009-07-08 Wisconsin Alumni Research Foundation Colchicine neoglycosides and methods for their synthesis and use
CL2007002904A1 (es) 2006-10-10 2008-06-06 Amgen Inc Soc Organizada Bajo Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras.
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
US8193373B2 (en) 2006-12-11 2012-06-05 Allergan, Inc. Therapeutic compounds
GB0624757D0 (en) 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
JP2010513569A (ja) 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20080153832A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153880A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
EP2124912B1 (en) 2006-12-22 2014-12-03 Allergan, Inc. Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20100011786A1 (en) * 2006-12-28 2010-01-21 Lg Electronics Inc. Ice making system and method for ice making of refrigerator
CA2675111C (en) 2007-01-11 2016-04-05 Novo Nordisk A\S Urea glucokinase activators
WO2008101064A1 (en) * 2007-02-14 2008-08-21 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
WO2008141013A1 (en) * 2007-05-08 2008-11-20 Allergan, Inc. S1p3 receptor inhibitors for treating pain
RS54332B9 (sr) 2007-05-15 2019-10-31 Merial Inc Ariloazol-2-il cijanoetilamino jedinjenja, postupci dobijanja i postupci njihove primene
WO2008147815A1 (en) 2007-05-22 2008-12-04 Chemocentryx, Inc. 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
WO2008156721A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Diphenyl substituted alkanes
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
PT2175859E (pt) 2007-07-12 2012-06-06 Chemocentryx Inc Heteroarilpiridil- e fenil-benzenossulfonamidas condensadas como moduladores de ccr2 para o tratamento de inflamação
WO2009012425A2 (en) * 2007-07-19 2009-01-22 Logigal Therapeutics, Inc. Compositions including leukotriene antagonists and nsaids and methods of using the same
EP2183227B1 (en) 2007-08-07 2014-09-24 Prosarix Limited 1,2,4-triazole derivatives as serotonergic modulators
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
ES2447940T3 (es) 2007-10-15 2014-03-13 The Salk Institute For Biological Studies Métodos para el tratamiento de varias enfermedades y afecciones, y compuestos útiles para los mismos
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US20110160265A1 (en) * 2007-10-18 2011-06-30 Luhrs Lauren M B Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2009058913A2 (en) * 2007-10-29 2009-05-07 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20090233921A1 (en) * 2008-03-11 2009-09-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7960379B2 (en) * 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
AU2009225747A1 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1P3 receptor inhibitors for treating inflammation
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
US8198318B2 (en) * 2008-03-18 2012-06-12 Allergen, Inc. Therapeutic amides
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2278879B1 (en) 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US7964634B2 (en) * 2008-04-24 2011-06-21 Allergan, Inc. Therapeutic compounds
DK2291368T3 (da) * 2008-04-24 2013-03-18 Allergan Inc Substitueret gamma-lactam som terapeutisk middel
WO2009132097A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2297084A1 (en) * 2008-04-24 2011-03-23 Allergan, Inc. Therapeutic compounds
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
US8569349B2 (en) * 2008-05-09 2013-10-29 Allergan, Inc. Therapeutic compounds
WO2009137413A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic cyclopentane derivatives
CA2723893A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic n-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives
KR20110031423A (ko) * 2008-05-09 2011-03-28 알러간, 인코포레이티드 치료학적 화합물
AU2009244539B2 (en) 2008-05-09 2014-07-10 Allergan, Inc. Therapeutic substituted hydantoins, and related compounds
JP2011520811A (ja) * 2008-05-09 2011-07-21 アラーガン インコーポレイテッド 治療用の置換チアゾリジノン類、オキサゾリジノン類および関連化合物
WO2009137411A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
EP2291353B1 (en) * 2008-05-20 2013-09-04 Allergan, Inc. Therapeutic prostaglandin compounds used as ocular hypotensive agents
CA2724467C (en) * 2008-05-20 2016-09-13 Allergan, Inc. Therapeutic lactams
US8541603B2 (en) * 2008-05-27 2013-09-24 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
EP2299813B1 (en) 2008-06-12 2015-12-16 Merck Sharp & Dohme Corp. Branched 3- and 6-substituted quinolines as cgrp receptor antagonists
CN105152919A (zh) 2008-07-28 2015-12-16 赛丹思科大学 用于治疗代谢疾病的化合物
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
CA2733247C (en) 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
PL3050874T3 (pl) 2008-11-14 2019-07-31 Merial Inc. Wzbogacone enancjomerycznie aryloazol-2-ilocyjanoetyloaminowe związki pasożytobójcze
EP2186521A1 (en) 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
EP2550962B1 (en) 2008-11-19 2019-10-30 Boehringer Ingelheim Animal Health USA Inc. Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
JP2012509879A (ja) 2008-11-21 2012-04-26 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー アダマンチルベンズアミド化合物
MX2011005726A (es) 2008-12-04 2011-07-29 Merial Ltd Derivados de avermectina y milbemicina dimericos.
CN102264227B (zh) 2008-12-22 2014-07-23 凯莫森特里克斯股份有限公司 C5aR拮抗剂
HUE026315T2 (en) 2009-01-23 2016-06-28 Rigel Pharmaceuticals Inc Preparations and methods for inhibiting the JAK pathway
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
AU2010213649A1 (en) 2009-02-13 2011-09-08 Allergan, Inc. 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1H-imidazole-2(3H)-thione
JP2012518007A (ja) 2009-02-13 2012-08-09 アラーガン インコーポレイテッド （３‐（１‐（１ｈ‐イミダゾール‐４‐イル）エチル）‐２‐メチルフェニル）メタノールを含む医薬組成物
MY152062A (en) 2009-02-24 2014-08-15 Merck Sharp & Dohme Indole derivatives as crth2 receptor antagonists
GB0904044D0 (en) 2009-03-09 2009-04-22 Sosei R & D Ltd The treatment of inflammatory disorders and pain
US20120107267A1 (en) 2009-03-11 2012-05-03 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
CN102448965B (zh) * 2009-04-02 2014-06-18 阿勒根公司 前列腺素e受体拮抗剂
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
CA2760775C (en) 2009-05-05 2019-03-05 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
PT2432454T (pt) 2009-05-19 2017-06-12 Neuroderm Ltd Composições para administração contínua de inibidores de dopa decarboxilase
WO2011009061A1 (en) 2009-07-17 2011-01-20 Allergan, Inc. Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
JP5738292B2 (ja) * 2009-07-28 2015-06-24 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
EP2464351A1 (en) 2009-08-11 2012-06-20 Allergan, Inc. Isothiozoles for treating conditions of the eye
CN102596246A (zh) * 2009-08-20 2012-07-18 Twi生物技术有限公司 诊断糖尿病及测定治疗疗效的方法
US20120190719A1 (en) 2009-08-26 2012-07-26 Allergan, Inc. Methods of treating motor disorders with alpha-2b andrenergic receptor agonists
AU2010289871B2 (en) 2009-09-02 2014-07-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2011034951A2 (en) 2009-09-15 2011-03-24 The Regents Of The University Of California Assisted enzyme replacement therapy
US8293925B2 (en) 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
JP5805646B2 (ja) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー アルツハイマー病の治療のための置換イミダゾール誘導体
CN102725261B (zh) 2009-11-25 2014-07-30 赛托麦蒂克斯有限公司 花生四烯酸类似物及用其进行镇痛治疗的方法
EP2507209B1 (en) 2009-12-04 2015-07-08 Merial, Inc. Pesticidal bis-organosulfur compounds
EP2512467A1 (en) 2009-12-17 2012-10-24 Merial Limited Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
ES2894036T3 (es) 2009-12-17 2022-02-11 Boehringer Ingelheim Animal Health Usa Inc Compuestos de dihidroazol antiparasitarios y composiciones que los comprenden
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
US9090584B2 (en) 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
CA2788078A1 (en) 2010-01-26 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusale M Ltd. Compositions and methods for prevention and treatment of pulmonary hypertension
US8299068B2 (en) * 2010-01-29 2012-10-30 Allergan, Inc. Therapeutically active cyclopentanes
BR112012019374B1 (pt) 2010-02-03 2022-01-11 Pharma Two B Ltd Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas
GB201002530D0 (en) 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
WO2011103091A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
EP2538783B1 (en) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
UA108641C2 (uk) 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
WO2011133600A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
EP2560643A1 (en) 2010-04-20 2013-02-27 Institute for OneWorld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
LT2576524T (lt) 2010-05-26 2017-12-27 Vtv Therapeutics Llc Metformino naudojimas kartu su gliukokinazės aktivatoriumi ir kompozicijos, apimančios metforminą ir gliukokinazės aktyvatorių
JP5857043B2 (ja) 2010-06-18 2016-02-10 大鵬薬品工業株式会社 Ｐｒｐｋ−ｔｐｒｋｂモジュレーター及びその使用
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
US8492424B2 (en) 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US8859606B2 (en) 2010-07-01 2014-10-14 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US9714238B2 (en) 2010-07-02 2017-07-25 Allergan, Inc. Therapeutic agents for ocular hypertension
WO2012003145A2 (en) 2010-07-02 2012-01-05 Allergan, Inc. Therapeutic agents for ocular hypertension
NZ621356A (en) 2010-07-02 2015-08-28 Univ Virginia Patent Found Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
BR112013001632B1 (pt) 2010-07-28 2021-05-25 Rigel Pharmaceuticals composto, composição farmacêutica, e, método de fabricar um composto
MX2013001234A (es) 2010-08-05 2013-04-24 Conrig Pharma Aps Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.
EP2605771B1 (en) 2010-08-16 2018-04-04 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
US8653118B2 (en) 2010-08-20 2014-02-18 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2012032513A1 (en) 2010-09-07 2012-03-15 Bar-Ilan University Boranophosphate derivatives for the treatment of osteoarthritis
US20130209368A1 (en) 2010-09-09 2013-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Near infrared fluorescent particles and uses thereof
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
HUE031661T2 (en) 2010-10-15 2017-07-28 Contera Pharma Aps Combinations of serotonin receptor agonists for the treatment of movement disorders
WO2012058532A2 (en) 2010-10-28 2012-05-03 Yale University Methods and compositions for assessing and treating cancer
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
TWI487706B (zh) 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
CN103442693A (zh) 2010-11-15 2013-12-11 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
MX2013005414A (es) 2010-11-16 2013-08-29 Centre Nat Rech Scient Derivados de monensina novedosos para el tratamiento y prevencion de infecciones por protozoarios.
DK2643470T3 (en) 2010-11-24 2016-05-17 Univ Yale Preparations and methods for treating ischemic injury with D-DT
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
CA2819457A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
GB201020860D0 (en) 2010-12-09 2011-01-26 Univ Wolverhampton Disulfiram formulation and uses thereof
NZ611620A (en) 2010-12-15 2016-02-26 Ciclofilin Pharmaceuticals Corp Cyclosporine analogue molecules modified at amino acid 1 and 3
WO2012087777A1 (en) 2010-12-22 2012-06-28 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide cgrp receptor antagonists
WO2012093383A1 (en) 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
EP3763419A1 (en) 2011-01-07 2021-01-13 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
MX339243B (es) 2011-02-03 2016-05-18 Vtv Therapeutics Llc Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
CN103501821A (zh) 2011-03-08 2014-01-08 艾克塞斯制药公司 用于递送活性剂穿过生物膜的靶向纳米载体系统
ES2686532T3 (es) 2011-03-10 2018-10-18 Rigel Pharmaceuticals, Inc. 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
DK2937349T3 (en) 2011-03-23 2017-02-20 Amgen Inc CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
CA2832422C (en) 2011-04-06 2020-07-28 Mcw Research Foundation, Inc. Epoxyeicosatrienoic acid analogs and methods of making and using the same
WO2012136221A1 (en) 2011-04-08 2012-10-11 Syddansk Universitet Ortho-fluoro substituted compounds for the treatment of metabolic diseases
EP2696897A2 (en) 2011-04-11 2014-02-19 Yeda Research and Development Co. Ltd. Albumin binding probes and drug conjugates thereof
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US20140294957A1 (en) 2011-04-18 2014-10-02 Maxdelbruck-Centrum Fur Molekulare Medizin Niclosamide for the treatment of cancer metastasis
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol
CA2835203A1 (en) 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions and methods for treating cancer
WO2012166533A1 (en) 2011-05-27 2012-12-06 Allergan, Inc. D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders
US20140221385A1 (en) 2011-06-01 2014-08-07 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
EP2720691A1 (en) 2011-06-17 2014-04-23 Allergan, Inc. D -serine for the treatment of visual system disorders
WO2013003168A1 (en) 2011-06-27 2013-01-03 Merial Limited Novel insect-repellent coumarin derivatives, syntheses, and methods of use
MX344911B (es) 2011-06-27 2017-01-11 Merial Inc Compuestos de eter amido-piridilico y composiciones y su uso contra parasitos.
WO2013005216A1 (en) 2011-07-05 2013-01-10 Radikal Therapeutics Inc. Compositions and methods for treatment of renal ischemia-reperfusion injury
AU2012287338A1 (en) 2011-07-25 2014-02-27 Allergan, Inc. N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors
US8609658B2 (en) 2011-07-27 2013-12-17 Allergan, Inc. N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
CA2848211A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
WO2013036290A1 (en) 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
EP2758377B1 (en) 2011-09-22 2017-08-02 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
EP2763535B1 (en) 2011-10-03 2017-06-07 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
US10391056B2 (en) 2011-11-03 2019-08-27 Taiwan Lipsome Company, LTD. Pharmaceutical compositions of hydrophobic camptothecin derivatives
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
CA2855954C (en) 2011-11-17 2020-09-01 Merial Limited Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof.
TWI531366B (zh) 2011-11-18 2016-05-01 善笙生物科技股份有限公司 牛樟芝在關節炎、軟骨破壞或軟骨細胞死亡的改善或預防的功效
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
KR102031846B1 (ko) 2011-12-01 2019-10-14 케모센트릭스, 인크. Ｃｃｒ(4) 길항제로서의 치환된 벤즈이미다졸 및 벤조피라졸
JP6141864B2 (ja) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
WO2013082373A1 (en) 2011-12-02 2013-06-06 Merial Limited Long-acting injectable moxidectin formulations and novel moxidectin crystal forms
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
AU2012358983B2 (en) 2011-12-21 2017-09-14 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
ES2702237T3 (es) 2011-12-21 2019-02-28 Allergan Inc Compuestos que actúan en receptores de prostaglandina múltiples que dan una respuesta antiinflamatoria general
EP2797893B1 (en) 2011-12-27 2017-11-22 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
US9090566B2 (en) 2011-12-27 2015-07-28 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
PT3263564T (pt) 2012-02-29 2020-09-10 Chemocentryx Inc Aza-aril 1h-pirazol-1-il benzeno sulfonamidas como antagonistas de ccr(9)
CA2865504A1 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP2015519309A (ja) 2012-04-16 2015-07-09 カネック ファーマ インコーポレイテッド Ｐｔｐ−１ｂインヒビター前駆体としての縮合芳香族ホスホナート誘導体
WO2013156861A2 (en) 2012-04-17 2013-10-24 University College Dublin, National University Of Ireland, Dublin Methods and compounds for treating proliferative disorders and viral infections
WO2013156871A2 (en) 2012-04-17 2013-10-24 University College Dublin, National University Of Ireland, Dublin Thromboxane receptor antagonists
PT2838517T (pt) 2012-04-18 2018-01-04 Contera Pharma Aps Formulação farmacêutica disponível sob forma oral adequada para a melhoria da gestão dos distúrbios da mobilidade
WO2013169567A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
EP2846801B1 (en) 2012-05-09 2017-04-05 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
US9227972B2 (en) 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US20150368197A1 (en) 2012-06-21 2015-12-24 Radikal Therapeutics Ins. Compositions and methods for treatment of inflammatory diseases of the lung
US9315508B2 (en) 2012-07-23 2016-04-19 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
US20140024621A1 (en) 2012-07-23 2014-01-23 Ms Therapeutics Limited Aminopyridine compounds and their uses
CN107184569A (zh) 2012-08-09 2017-09-22 迪纳米斯治疗公司 保持或改善对象健康、幸福和/或生理功能的方法
WO2014036022A1 (en) 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
CA2884710A1 (en) 2012-09-12 2014-03-20 Rigel Pharmaceuticals, Inc. Treatment for vitiligo
RU2668791C2 (ru) 2012-10-19 2018-10-02 ТиЭксПи ФАРМА ГМБХ АНАЛОГИ АЛЬФА- и ГАММА-MSH
JP6322200B2 (ja) 2012-11-16 2018-05-09 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒトホスファチジルイノシトール３−キナーゼデルタのプリン阻害剤
DK2922845T3 (en) 2012-11-20 2018-09-24 Merial Inc ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND PROCEDURES FOR USE THEREOF
AU2013355054B2 (en) 2012-12-07 2017-08-24 Chemocentryx, Inc. Diazole lactams
ES2648994T3 (es) 2012-12-21 2018-01-09 Chemocentryx, Inc. Diazolamidas como antagonistas del receptor CCR1
EP2945932B1 (en) 2013-01-21 2018-11-21 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US20140213555A1 (en) 2013-01-25 2014-07-31 Rigel Pharmaceuticals, Inc. Compounds and method for treating autoimmune diseases
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
HRP20180459T1 (hr) 2013-03-05 2018-05-04 Salzman Group, Inc. Prolijekovi multifunkcionalnih nitroksidnih derivata i njihova primjena
WO2014141261A1 (en) 2013-03-13 2014-09-18 Neuroderm Ltd Method for treatment of parkinson's disease
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
CA3051327A1 (en) 2013-03-15 2014-09-18 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
US9051294B2 (en) 2013-04-30 2015-06-09 Allergan, Inc. Therapeutic agents
US9000032B2 (en) 2013-05-31 2015-04-07 Allergan, Inc. Substituted cyclopentenes as therapeutic agents
US10117841B2 (en) 2013-07-02 2018-11-06 Ecoplanet Environmental Llc Volatile organic compound formulations having antimicrobial activity
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
WO2015026683A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN104546830B (zh) 2013-10-23 2018-03-09 善笙生物科技股份有限公司 来自牛樟芝菌丝体的化合物及混合物的用途
US9315486B2 (en) 2013-10-29 2016-04-19 Allergan, Inc. Therapeutic cyclopentanols, compositions thereof, and methods for use thereof
NZ719916A (en) 2013-11-01 2017-09-29 Merial Inc Antiparasitic and pesticidal isoxazoline compounds
WO2015073344A1 (en) 2013-11-14 2015-05-21 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
KR102331833B1 (ko) 2013-12-02 2021-11-25 케모센트릭스, 인크. Ccr6 화합물
WO2015094864A1 (en) 2013-12-20 2015-06-25 Allergan, Inc. Secondary amines as therapeutic agents
CA2945687A1 (en) 2014-01-27 2015-07-30 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ活性化合物の錠剤製剤
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
RU2016142145A (ru) 2014-04-22 2018-05-22 ТиЭксПи ФАРМА ГМБХ Пептидные аналоги с разветвленным аминокислотным зондом (зондами)
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
US9394273B2 (en) 2014-05-15 2016-07-19 Allergan, Inc. Therapeutic prostaglandin receptor agonists
JP6616786B2 (ja) 2014-05-19 2019-12-04 メリアル インコーポレイテッド 駆虫性化合物
US9573926B2 (en) 2014-05-22 2017-02-21 Allergan, Inc. Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
CN106458859B (zh) 2014-06-06 2019-08-30 阿勒根公司 作为治疗性化合物的新型ep4激动剂
US9908923B2 (en) 2014-06-11 2018-03-06 The Medical College Of Wisconsin, Inc. Monomeric CXCL121 peptide and methods of use thereof
WO2016009341A1 (en) 2014-07-14 2016-01-21 Radikal Therapeutics Inc. Thioredoxin mimetic prodrugs and uses thereof
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EP3190889B1 (en) 2014-09-03 2021-11-17 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
MA40592A (fr) 2014-10-06 2016-04-14 Chemocentryx Inc Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
CN111961050A (zh) 2014-12-02 2020-11-20 普拉纳生物技术有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物
US10137096B2 (en) 2014-12-09 2018-11-27 Ezekiel Golan Binge behavior regulators
EP4186521A1 (en) 2015-02-20 2023-05-31 The Board of Trustees of the Leland Stanford Junior University Mixed allergen compositions and methods for using the same
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
JP2018507914A (ja) 2015-03-09 2018-03-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
KR20250078598A (ko) 2015-05-19 2025-06-02 예일 유니버시티 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
CN107835818B (zh) 2015-05-20 2022-04-29 勃林格殷格翰动物保健美国公司 驱虫缩酚酸肽化合物
MA42145B1 (fr) 2015-05-20 2020-05-29 Amgen Inc Triazoles agonistes du récepteur apj
AU2016271292B2 (en) 2015-06-03 2022-04-14 The Medical College Of Wisconsin, Inc. An engineered CCL20 locked dimer polypeptide
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
EP4014984A1 (en) 2015-06-15 2022-06-22 The Board of Trustees of the Leland Stanford Junior University Compositions for use in treating aging-associated conditions
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
US9932304B2 (en) 2015-06-16 2018-04-03 University College Dublin, National University Of Ireland, Dublin Thromboxane receptor antagonists
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
NO346258B1 (en) 2015-06-30 2022-05-16 Neurad Ltd Novel breathing control modulating compounds, and methods of making and using same
GB2556002B (en) 2015-07-07 2020-12-16 Bluewillow Biologics Inc Methods and compositions for nanoemulsion vaccine formulations
US11161801B2 (en) 2015-08-10 2021-11-02 Ramot At Tel-Aviv University Ltd. Cationic pillararenes and uses thereof
WO2017077528A2 (en) 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
US10660884B2 (en) 2015-11-02 2020-05-26 University Of Rochester Phosphonate-chloroquine conjugates and methods using same
CN108473532A (zh) 2015-11-02 2018-08-31 罗切斯特大学 硼替佐米缀合物和其使用方法
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
CA3005142A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
MX2018008624A (es) 2016-01-14 2018-12-10 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
WO2017127409A1 (en) 2016-01-20 2017-07-27 Chemocentryx, Inc. 2-oxindole compounds
US11033630B2 (en) 2016-02-11 2021-06-15 Mordechai Chevion Method and pharmaceutical composition for treatment of neurodegeneration
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2017153977A1 (en) 2016-03-08 2017-09-14 Salzman Lovelace Investments, Ltd. Solid formulations of resolvins and uses thereof
JP7121722B2 (ja) 2016-04-04 2022-08-18 ケモセントリックス，インコーポレイティド 可溶性Ｃ５ａＲアンタゴニスト
US10946020B2 (en) 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
US10583196B2 (en) 2016-06-03 2020-03-10 Novacyte, Inc. Polymer linkers and their uses
US10036024B2 (en) 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
WO2018039508A1 (en) 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
WO2018071535A1 (en) 2016-10-14 2018-04-19 Merial, Inc. Pesticidal and parasiticidal vinyl isoxazoline compounds
CN110325542A (zh) 2016-11-03 2019-10-11 劳伦斯·I·吴 克罗拉滨的前体药物
TWI794190B (zh) 2016-11-07 2023-03-01 加拿大商愛彼特生物製藥公司 含有取代的吡啶酮之三環化合物及其使用方法
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093920A1 (en) 2016-11-16 2018-05-24 Merial, Inc. Anthelmintic depsipeptide compounds
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
KR102754341B1 (ko) 2016-11-23 2025-01-13 케모센트릭스, 인크. 국소 분절 사구체경화증의 치료 방법
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
EP4095135A1 (en) 2016-12-14 2022-11-30 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
EP3601216B1 (en) 2017-03-21 2023-10-25 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
TW201902507A (zh) 2017-04-14 2019-01-16 美商康特維爾製藥公司 治療病毒感染之組合療法
DE202017002464U1 (de) 2017-05-09 2017-06-12 St. Lotus Biotech Corp. Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall
US11484543B2 (en) 2017-05-18 2022-11-01 The Rockefeller University Compositions and methods for diagnosing and treating diseases and disorders associated with mutant KCNJ5
CA3068254A1 (en) 2017-06-20 2018-12-27 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
EP3664793B1 (en) 2017-08-08 2022-06-29 ChemoCentryx, Inc. Macrocyclic immunomodulators
HUE061497T2 (hu) 2017-08-14 2023-07-28 Boehringer Ingelheim Animal Health Usa Inc Peszticid és paraziticid hatású pirazol-izoxazolin vegyületek
EP3672936A4 (en) 2017-08-23 2021-05-19 Gavish-Galilee Bio Applications Ltd COMPOSITIONS AND METHODS OF TREATMENT ATHEROSCLEROTIC CARDIOVASCULAR DISEASES
SG11202002119QA (en) 2017-09-25 2020-04-29 Chemocentryx Inc Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
SG11202002975YA (en) 2017-10-11 2020-04-29 Chemocentryx Inc Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
CN111818929A (zh) 2017-11-27 2020-10-23 由卫生与公众服务部部长代表的美利坚合众国 用于治疗和/或预防牙周疾病的化合物、组合物和方法
EP3728202A4 (en) 2017-12-22 2021-05-26 ChemoCentryx, Inc. Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
CA3085946A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as c5ar inhibitors
US11207294B2 (en) 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
WO2019141957A1 (en) 2018-01-19 2019-07-25 Cado Biotechnology Ivs N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
EP3749096A1 (en) 2018-02-08 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
JP2021513553A (ja) 2018-02-13 2021-05-27 ビートルバング ファーマ リミテッド カンナビノイド誘導体並びにそのコンジュゲート及びその使用
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2019166877A1 (en) 2018-03-02 2019-09-06 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
US11608336B2 (en) 2018-04-02 2023-03-21 Chemocentryx, Inc. Prodrugs of fused-bicyclic C5aR antagonists
EP3552605A1 (en) 2018-04-11 2019-10-16 Univerzita Palackého V Olomouchi Mcoppb for use as medicament
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
EP3802524A1 (en) 2018-05-29 2021-04-14 Cersci Therapeutics, Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2019236984A1 (en) 2018-06-08 2019-12-12 The Medical College Of Wisconsin, Inc. Methods of treating vascular leakage using cxcl12 peptides
CN112996788B (zh) 2018-07-09 2024-07-16 勃林格殷格翰动物保健美国公司 驱蠕虫的杂环化合物
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
CN112789037A (zh) 2018-09-06 2021-05-11 创新药物筛选有限公司 用于治疗哮喘或帕金森病的方法和药物组合物
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
EP3866794B1 (en) 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3873471A4 (en) 2018-10-31 2022-06-15 Merck Sharp & Dohme Corp. N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
WO2020112374A1 (en) 2018-11-20 2020-06-04 Boehringer Ingelheim Animal Health USA Inc. Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
CN119285648A (zh) 2019-03-19 2025-01-10 勃林格殷格翰动物保健有限公司 驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物
IL287617B2 (en) 2019-05-09 2024-11-01 Feinstein Institutes For Medical Research Hmgb1 antagonist
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
EP3980412B1 (en) 2019-06-06 2025-08-13 Merck Sharp & Dohme LLC 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
AU2020311879A1 (en) 2019-07-08 2022-01-27 Activesite Pharmaceuticals, Inc. Processes for preparing plasma kallikrein inhibitors
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
CA3147444A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
PH12022550877A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
AU2020368393A1 (en) 2019-10-16 2022-04-21 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
EP4054541A4 (en) 2019-11-08 2023-12-20 ChemoCentryx, Inc. Salt forms of a complement component c5a receptor
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
MX2022011755A (es) 2020-03-27 2022-11-16 Aclaris Therapeutics Inc Proceso, composiciones y formas cristalinas de compuestos de piridinona-piridinilo sustituidos.
TW202203916A (zh) 2020-03-31 2022-02-01 美商卡默森屈有限公司 使用ｃｃｒ９抑制劑及抗ｉｌ—２３阻斷抗體治療發炎性腸道疾病的組成物及方法
CN116134144A (zh) 2020-04-23 2023-05-16 Az治疗股份有限公司 细胞的hla-i类mhc消融
EP3901160A1 (en) 2020-04-25 2021-10-27 Nuvamid SA Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
WO2021214299A1 (en) 2020-04-24 2021-10-28 Nuvamid Sa Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
US11357865B2 (en) 2020-04-27 2022-06-14 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
US20230172878A1 (en) 2020-04-30 2023-06-08 Annette M. Tobia Compositions and methods for treating cytokine storms
JP2023531378A (ja) 2020-05-28 2023-07-24 エーゼットセラピーズ， インコーポレイテッド 神経変性疾患を治療するためのＣＡＲ－Ｔｒｅｇ系療法
BR112022024156A2 (pt) 2020-05-29 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Compostos heterocílicos antelmínticos
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
MX2023000447A (es) 2020-07-07 2023-04-20 Atxa Therapeutics Ltd Antagonista de receptor de tromboxano formulaciones.
US20230287031A1 (en) 2020-07-17 2023-09-14 Université De Bretagne Occidentale New glycolipids and use thereof as sk3 ion channel modulators
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited MIGRAINE TREATMENT
WO2022029275A1 (en) 2020-08-06 2022-02-10 Nuvamid Sa Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
CA3187851A1 (en) 2020-08-07 2022-02-10 Guillaume BERMOND Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity
WO2022034062A1 (en) 2020-08-12 2022-02-17 Txp Pharma Ag Exendin-4 peptide analogues
CA3198225A1 (en) 2020-10-13 2022-04-21 Betavive Ltd. Method and compounds for treating diabetes and associated metabolic diseases
GB202017255D0 (en) 2020-10-30 2020-12-16 Queens Univ Of Belfast Immunomodulatory agent
GB202017251D0 (en) 2020-10-30 2020-12-16 Queens Univ Of Belfast Neurodegenerative treatment
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11730733B2 (en) 2020-12-10 2023-08-22 Imbria Pharmaceuticals, Inc. Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
US11969422B2 (en) 2020-12-10 2024-04-30 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
US11793807B2 (en) 2020-12-10 2023-10-24 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
US12076318B2 (en) 2020-12-10 2024-09-03 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
EP4241837A3 (en) 2020-12-18 2023-11-08 Nuvamid SA Nicotinamide mononucleotide derivatives in the treatment and prevention of sickle cell disease
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
CN116940350A (zh) 2021-02-08 2023-10-24 博施健康爱尔兰有限公司 预防、治疗或改善溃疡性结肠炎的阿米莫德
WO2022184685A1 (en) 2021-03-01 2022-09-09 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof for the treatment and/or prevention of long covid-19
EP4070799A1 (en) 2021-04-08 2022-10-12 Nuvamid SA Compositions for the improvement of sport performance
EP4079310A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
EP4079311A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
WO2022254425A1 (en) 2021-05-31 2022-12-08 Cannabotech Ltd. Compositions comprising a cannabinoid and uses thereof
EP4355335A1 (en) 2021-06-17 2024-04-24 Nuvamid SA Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction
WO2022263676A1 (en) 2021-06-18 2022-12-22 University Of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
US20240335466A1 (en) 2021-08-02 2024-10-10 Nuvamid Sa Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
US20230120635A1 (en) 2021-10-12 2023-04-20 Betavive Ltd. Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases
TW202423928A (zh) 2022-09-02 2024-06-16 美商默沙東有限責任公司 源自依克沙替康(exatecan)之拓樸異構酶-1抑制劑醫藥組合物及其用途
IL319372A (en) 2022-09-06 2025-05-01 Hadasit Med Res Service Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders
AU2023366166A1 (en) 2022-10-25 2025-05-01 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
AU2023397331A1 (en) 2022-12-14 2025-06-26 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
AU2024210234A1 (en) 2023-01-20 2025-05-22 Epics Therapeutics Piperidine derivatives as mettl3 inhibitors
WO2024194175A1 (en) 2023-03-17 2024-09-26 Atmosr Adenine derivatives as hsp90 inhibitors
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease
WO2025011733A1 (en) 2023-07-07 2025-01-16 Nuvamid Sa Nicotinamide mononucleotide and derivatives thereof and use thereof in the treatment and prevention of polycythemia
TW202513071A (zh) 2023-08-14 2025-04-01 以色列商琉璃藥品 (1991) 有限公司 Gal475組合物及其使用方法
WO2025064408A1 (en) 2023-09-18 2025-03-27 The Broad Institute, Inc. Compositions and methods for treating cardiovascular disease
WO2025099725A1 (en) 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
GB2636364A (en) 2023-12-07 2025-06-18 Aramune Tech Limited Arabinogalactan
WO2025134072A1 (en) 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
WO2025176994A1 (en) 2024-02-20 2025-08-28 Analytical Services For Art & Archaeology (Scotland) Ltd Composition and method of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2211485A (en) * 1940-08-13 Effervescent acetyl salicylic acid
US536155A (en) * 1895-03-19 Pill or tablet
US2312381A (en) * 1940-10-24 1943-03-02 Frank J Bickenheuser Medicinal tablet
US3062715A (en) * 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
GB917456A (en) * 1958-10-30 1963-02-06 Casco Lab Inc Suppository composition and preparation thereof
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3136692A (en) * 1961-06-30 1964-06-09 Strong Cobb Arner Inc Effervescent composition containing polyvinylpyrrolidone
GB1093286A (en) * 1965-02-15 1967-11-29 Biorex Laboratories Ltd Improvements in or relating to dosage unit forms for the administration of medicaments and diagnostic agents
FR5391M (forum.php) * 1965-11-04 1967-10-23
GB1123316A (en) * 1966-12-09 1968-08-14 Wynlit Pharmaceuticals Trust R Improvements in suppositories
US3495001A (en) * 1968-05-27 1970-02-10 Miles Lab Effervescent compositions of acetylsalicylic acid
US3887700A (en) * 1969-11-28 1975-06-03 Aspro Nicholas Ltd Analgesic formulations
US3764668A (en) * 1970-09-30 1973-10-09 Interx Research Corp Compositions of salts of salicylamide
US3676549A (en) * 1970-09-30 1972-07-11 Alza Corp Administration of alkali metal salts of salicylamide
GB1359614A (en) * 1971-04-06 1974-07-10 Dev Et De Rech Soc Fr De Method for the manufacture of effervescent tablets
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150137871A (ko) * 2014-05-30 2015-12-09 디씨에스이엔지 주식회사 회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치

Also Published As

Publication number Publication date
ES8307092A1 (es) 1983-06-16
GR73519B (forum.php) 1984-03-09
IE51216B1 (en) 1986-11-12
PT72796B (fr) 1982-03-30
EP0040899B1 (en) 1984-09-12
DK152482C (da) 1988-08-01
EP0040899A2 (en) 1981-12-02
PT72796A (fr) 1981-05-01
DE3165901D1 (en) 1984-10-18
ES510822A0 (es) 1983-06-16
ATE9267T1 (de) 1984-09-15
ES267593Y (es) 1983-11-16
JPS56167617A (en) 1981-12-23
ES267593U (es) 1983-05-16
NZ196561A (en) 1983-05-10
DK184681A (da) 1981-10-26
DK152482B (da) 1988-03-07
IE810765L (en) 1981-10-25
US4265874A (en) 1981-05-05
EP0040899A3 (en) 1982-08-11

Similar Documents

Publication Publication Date Title
JPH044293B2 (forum.php)
US4344929A (en) Method of delivering drug with aid of effervescent activity generated in environment of use
JP2683359B2 (ja) 固体の性質を有する移動可能マトリツクスを含有する投与用製剤
JP3301612B2 (ja) ローディングドースを含む長期配送デバイス
KR100246157B1 (ko) 약물 전달의 지연 활성화 삼투 장치
US4320759A (en) Dispenser with diffuser
US4309996A (en) System with microporous releasing diffusor
JPS60103959A (ja) 浸透性カプセル
US5198229A (en) Self-retaining gastrointestinal delivery device
JPS59167513A (ja) 速効性浸透圧利用薬剤放出システム
JP2925145B2 (ja) 多層投与系
US4235236A (en) Device for dispensing drug by combined diffusional and osmotic operations
DE3625915C2 (de) Abgabevorrichtung zur Freisetzung eines Wirkstoffs
JPH0428242B2 (forum.php)
JPH0575725B2 (forum.php)
JPS61249916A (ja) 不活性なコア部を有する浸透圧利用薬剤投与具
JPH0196116A (ja) 急速な薬剤配送と引続く緩徐な薬剤配送からなる投薬形
JPH05502215A (ja) ヒドロゲル駆動要素を含む口腔浸透デバイス
CN1331580A (zh) 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
EP0250083B1 (en) Dosage form with means for governing rate of gas formation
JPH0291017A (ja) 溶解度を調節した医薬供給装置
JPS6244249A (ja) 有効剤組成物を反芻動物に投与するための投与デイバイス
JPH11505842A (ja) 高い薬物負荷を有する浸透デバイスと、薬物投与の遅延活性化
CN112741817A (zh) 一种新型泡腾制剂给药系统